Table 2

Percent viability and extent of wing defect with vg-GAL4 for additional UAS transgenic lines

% viability vg-GAL4

% viable flies strong wing defect

% viable flies mild wing defect

% viable flies no wing defect


UAS-Bax-GFP

9.5

41.3

55.1

0.03

(BA13I)

(29/303)

(12/29)

(16/29)

(1/29)

UAS-Bax30–192-GFP

12

65.2

30.4

4.3

(DBA8IA)

(26/216)

(15/26)

(7/26)

(1/26)

UAS-Bax-GFP;

78.6

0

0

100

UAS-Bcl-2 (BA13I;BC24III)

(48/61)

(0/48)

(0/48)

(48/48)

UAS-Bax30–192- GFP;

35.09

84.9

15.09

0

UAS-Bcl-2 (DBA8IA; BC24III)

(53/151)

(45/53)

(8/53)

(0/53)


Additional UAS transgenic lines for Bax-GFP (BA13I) or Bax 30–192-GFP (DBA8IA) or Bax-GFP+Bcl-2 (BA13I; BC24III) or Bax 30–192-GFP+Bcl-2 (DBA8IA; BC24III) driven by vg-GAL4 were assessed for the viability of flies at 25°C as described in Figure 2B. The eclosed adult flies expressing Bax-GFP or Bax 30–192-GFP were analyzed for the extent of wing defect and categorized as depicted in Figure 2I. The percentage of flies for the wing defect was calculated with respect to the total number of eclosed flies expressing Bax-GFP or Bax 30–192-GFP. Numbers in parenthesis indicate flies screened for analysis.

Parikh et al. BMC Cell Biology 2007 8:16   doi:10.1186/1471-2121-8-16

Open Data